Howe & Rusling’s Cocrystal Pharma COCP Stock Holding History

Howe & Rusling’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21	Closed	–	–	961
2020 Q4	$0	Buy	+21	New	+$292	﹤0.01%	944

Other funds holding COCP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Howe & Rusling's COCP Position: Q1 2021 in Review

Howe & Rusling sold out of Cocrystal Pharma (COCP) in Q1 2021, closing a stake of 21 shares.

Howe & Rusling first reported a position in COCP in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 35 funds tracked by Wall St. Rank hold COCP as of Q1 2021.

Howe & Rusling reported no remaining Cocrystal Pharma position as of Q1 2021 after selling out during the quarter.
Howe & Rusling sold 21 Cocrystal Pharma shares in Q1 2021.
Howe & Rusling first reported a position in Cocrystal Pharma in Q4 2020 and held it in 1 quarter.
Howe & Rusling's Cocrystal Pharma position peaked at $0 in Q4 2020.
35 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2021.

Based on Howe & Rusling's 13F filing for Q1 2021, filed 13 May 2021.